Navigation Links
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Date:3/31/2008

cument.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. P-LLY

This press release contains forward-looking statements about the potential of the investigational compound LY450139 and reflects Lilly's current beliefs. However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the product will receive regulatory approvals, or that the regulatory approval will be for the indication(s) anticipated by the company. There is also no guarantee that the product will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) Small, GW, Rabins, PV, Barry, PP, Buckholtz, NS, DeKosky, ST,

Ferris, SH, Finkel, SI, Gwyther, LP, Khachaturian, ZS, Lebowitz, BD,

McRae, TD, Morris, JC, Oakley, F, Schneider, LS, Streim, JE,

Sunderland, T, Teri, LA, Tune LE. Diagnosis and Treatment of

Alzheimer Disease and Related Disorders: Consensus Statement of the

American Association for Geriatric Psychiatry, the Alzheimer's

Association, and the American Geriatrics Society. JAMA 1997; 278:

1363-1371.

(2) Alzheimer's Association. "2008 Alzheimer's Disease Facts and


'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. Lilly Receives NCQA Design Certification for Depression Care Management Program
6. Lilly and Glenmark Pharmaceuticals Announce License Agreement
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
11. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... SEOUL, South Korea and FREMONT, Calif. ... (NCC) of South Korea and Velos, ... the use of Velos eResearch for cancer research nationally throughout ... with other research partners. The recent agreement signing was accompanied ... in Seoul , South Korea.  ...
(Date:7/7/2015)... 30, 2015 ... the addition of the "Biomedical Photoacoustic ... offering. This patent landscape focuses ... is a safe, non-invasive, non-ionizing imaging technique. ... a great alternative to traditional medical imaging ...
(Date:7/7/2015)... , 7 de julio de 2015 /PRNewswire/ ... de propiedad privada centrada en el desarrollo de ... neurovascular, ha anunciado hoy que R. Michael ... directiva. Kleine cuenta con más ... de los dispositivos médicos y la sanidad. Ha ...
Breaking Medicine Technology:National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 2Worldwide Biomedical Photoacoustic Imaging Patent Landscape Report 2015 3Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3
... March 11, 2011, the United States District Court for ... a portion of the patent litigation brought by Cephalon ... wholly-owned subsidiary CIMA Labs, Inc., ("CIMA") against Watson Pharmaceuticals, ... "Watson") pertaining to Cephalon,s FENTORA® fentanyl buccal tablet product. ...
... (Nasdaq: ONXX ) today announced that it will ... Thursday, March 17, 2011 at 10:15 a.m. Eastern Time (7:15 ... a live webcast of the presentation on our website at: ... recommended that listeners log on 15 minutes early in order ...
Cached Medicine Technology:Court Rules on First Set of Patents in FENTORA Litigation 2Onyx Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:7/7/2015)... ... , ... U.S. Rep. Mike Thompson (D-CA 5) introduced legislation ... available to Medicare beneficiaries. Thompson’s bill, the Medicare Telehealth Parity Act, was introduced ... and Peter Welch (D-VT). , “This bi-partisan legislation takes an important step forward ...
(Date:7/7/2015)... ... ... Today, the physicians at Allied Anesthesia, who provide services to Children’s Hospital of ... a series of tips to help children stay safe over the summer months. , ... unsupervised time outdoors. , The most common causes of injuries and death for ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... everyday items, recently launched their first line of luxury smart jewelry called the ... is expected to ship this fall. , “The Socialite collection was crafted ...
(Date:7/7/2015)... and CHICAGO (PRWEB) , ... July 07, 2015 ... ... healthcare business development and growth strategy expert Jay Warden as Senior Vice President, ... for the company’s efforts to provide the best solutions to healthcare providers’ needs ...
(Date:7/7/2015)... PHOENIX, (PRWEB) , ... July ... ... Western Refining convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial ... camp mobile program, surpassing their original 2015 fundraising goal by nearly $100,000, ...
Breaking Medicine News(10 mins):Health News:The American Telemedicine Association Supports Legislation to Expand Medicare Coverage for Telemedicine Services 2Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 2Health News:Allied Anesthesia Physicians Release Summertime Safety Tips 3Health News:WiseWear Unveils Luxury Smart Jewelry Line 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3
... The chemical (S)-N,-nitrosonornicotine, or (S)-NNN, which is present ... according to results presented at the AACR Annual Meeting ... Although smokeless tobacco products have long been linked ... cancers, this is the first study to identify a ...
... 2 (HealthDay News) -- When parents say their child,s urine ... Canadian researchers report. To examine the link between smelly ... Hospital Center at the University of Montreal surveyed the parents ... 3 years who were tested in the emergency room for ...
... reprogram scar tissue resulting from myocardial infarction (MI) into ... CardioVascular Biology (FCVB) 2012 meeting, held 30 March to 1 ... London. In a keynote lecture Dr Deepak Srivastava ... changer" with the potential to revolutionise treatment of MI. ...
... can be used to predict cancer recurrence in men ... therapy. The clinical research, led by radiation oncologists ... Health Network (UHN) is published online today in ... American Association for Cancer Research (doi: 10.1158/1078-0432.CCR-11-2711). ...
... The antiangiogenic drug pazopanib has demonstrated clinically meaningful ... results presented at the AACR Annual Meeting 2012, held ... revealed that increases in interleukin-8 levels early after treatment ... to the therapy. "Historically, prognosis of patients with ...
... (HealthDay News) -- The health effects of early life exposure ... in boys, a new study finds. University of Cincinnati ... were exposed to high levels of secondhand smoke and also ... for decreased lung function at age 7. The investigators ...
Cached Medicine News:Health News:Strong oral carcinogen identified in smokeless tobacco 2Health News:Smelly Urine a Red Flag for Kids' UTI 2Health News:Transforming scar tissue into beating hearts: The next instalment 2Health News:Transforming scar tissue into beating hearts: The next instalment 3Health News:Transforming scar tissue into beating hearts: The next instalment 4Health News:Oxygen in tumors predicts prostate cancer recurrence 2Health News:Biomarker identified in relation to drug response in refractory urothelial cancer 2Health News:Secondhand Smoke Affects Young Girls More Than Boys: Study 2
For the quantitative determination of total protein in serum. Linearity: 1-15 g/dl....
... Intended for the quantitative ... serum. Reaction: kinetic, lag phase ... followed by linear phase of ... 340 nm. Linearity: 100 mg/dL ...
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
Medicine Products: